

Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity among healthcare workers in a large U.S. healthcare system

## Authors

Julia M. Baker\*, PhD,<sup>1</sup> Kristin N. Nelson\*, PhD,<sup>1</sup> Elizabeth Overton, MSPH,<sup>2</sup> Benjamin A. Lopman, PhD,<sup>1</sup> Timothy L. Lash, DSc,<sup>1</sup> Mark Photakis, BBA,<sup>2</sup> Jesse T. Jacob, MD,<sup>3</sup> John Roback, MD PhD,<sup>3</sup> Scott K. Fridkin, MD,<sup>3</sup> James P. Steinberg, MD<sup>3</sup>

\* These authors contributed equally to this work.

## Affiliations

<sup>1</sup> Rollins School of Public Health, Emory University, Georgia, USA

<sup>2</sup> Emory Healthcare, Georgia, USA

<sup>3</sup> Emory University School of Medicine, Emory University, Georgia, USA

## Supplement

**eFigure 1.** Number of study participants (A) and cumulative incidence of COVID-19 (B) by zip code <sup>a</sup>


**eTable 1.** Details of data sources and factor descriptions

**eTable 2.** Additional descriptive statistics for survey participants. (n=9,610)


**eTable 3.** STROBE statement- checklist of items that should be included in reports of observational studies

**eFigure 1. Number of study participants (A) and cumulative incidence of COVID-19 (B) by zip code <sup>a</sup>**

**A**



**B**



<sup>a</sup> Data for zip codes with fewer than 10 study participants are excluded from the figure.

**eTable 1. Details of data sources and factor descriptions.**

<b>Factor</b>	<b>Data source</b>	<b>Survey question</b>	<b>Possible responses</b>	<b>Additional information</b>
<b>Demographic and community factors</b>				
Age group	Employment records	NA	NA	Categorized into deciles
Race	Employment records	NA	NA	Self-reported
Ethnicity	Employment records	NA	NA	Self-reported
Contact with confirmed/suspected positive individual(s)	Survey	Since February 1, 2020, have you had close contact (>10 minutes of face to face) with someone with confirmed or suspected COVID-19 outside of work?	1. Yes exposed to someone with COVID-19; 2. Yes; 3. No; 4. Not sure	Categorized into yes/no (not sure categorized as "no")
Residential COVID-19 incidence	Georgia Department of Public Health and employment records (residential zip code)	NA	NA	Cumulative incidence of persons under investigation for COVID-19 linked with zip code data and week of serology test. Cumulative incidence two weeks prior to week of serology test was used to account for lag between infection and testing.
<b>Occupational factors</b>				
Caring for COVID-19 positive patient(s)	Survey	While at work, did/do you provide direct patient care for any patient(s) known (confirmed) to be positive for COVID-19, regardless of location in the facility?	Yes; No; Unknown	Unknown categorized as "no"

**eTable 1. Details of data sources and factor descriptions (continued).**

Factor	Data source	Survey question	Possible responses	Additional information
Caring patient(s) found to be COVID-19 positive while not on isolation precautions	Survey	While at work, did you care for patient(s) who, while not on isolation precautions, were tested and found to be COVID-19 positive?	Yes; No; Not sure	Not sure categorized as "no"
Contact with other healthcare worker found to be COVID-19 positive	Survey	While at work, did you have close contact (>10 minutes face to face) to other healthcare worker(s) who were found to have COVID-19 infection during the time period you were exposed to them?	Yes; No; Not sure	Not sure categorized as "no"
Workplace location	Survey	Where do/did you spend most time at work in the hospital during the COVID-19 pandemic? (may check more than one if you split your time equally)	<ol style="list-style-type: none"> <li>1. Emergency department;</li> <li>2. Medical-surgical focused on COVID-19 patients;</li> <li>3. Medical-surgical-not focused on COVID-19 patients;</li> <li>4. ICU focused on COVID-19 patients;</li> <li>5. ICU-not focused on COVID-19 patients</li> <li>6. Clinic focused on COVID-19 patients;</li> <li>7. Clinic not focused on COVID-19 patients;</li> <li>8. OR or peri-operative area;</li> <li>9. Other procedure area;</li> <li>10. Other hospital area;</li> <li>11. Non-clinical area of hospital/clinic</li> <li>12. Not in hospital or clinic;</li> <li>13. Work from home: worked from home</li> </ol>	<p>Hierarchy to classify participant into one category (even if multiple job locations were selected) in the order below. Order based on anticipated encounters with COVID-19 positive patients.</p> <ol style="list-style-type: none"> <li>1. Emergency department: emergency department</li> <li>2. COVID-19 focused: medical-surgical focused on COVID-19 patients; ICU focused on COVID-19 patients; clinic focused on COVID-19 patients</li> <li>3. Inpatient not COVID-19 focused: medical-surgical-not focused on COVID-19 patients; ICU-not focused on COVID-19 patients</li> <li>4. Outpatient clinical: clinic not focused on COVID-19 patients</li> <li>5. OR/procedure: OR or peri-operative area; other procedure area</li> <li>6. Other hospital area: other hospital area</li> <li>7. No patient contact: non-clinical area of hospital/clinic; not in hospital or clinic</li> <li>8. Work from home: worked from home</li> <li>9. Not specified: no job location selected in survey</li> </ol>

**eTable 1. Details of data sources and factor descriptions (continued).**

Factor	Data source	Survey question	Possible responses	Additional information
Workplace role	Survey	What is your job role?	<ol style="list-style-type: none"> <li>1. Advanced practice provider</li> <li>2. Environmental services</li> <li>3. Nurse</li> <li>4. Nurse technician</li> <li>5. Other direct care provider</li> <li>6. Other with no patient contact</li> <li>7. Physician</li> <li>8. Radiology technician</li> <li>9. Respiratory therapist</li> </ol>	
PPE use	Survey	While at work, please assess your use of workplace recommended personal protective equipment (PPE) while caring for patients with suspected or known COVID-19.	<ol style="list-style-type: none"> <li>1. Had numerous situations where I was not using recommended PPE;</li> <li>2. Wore PPE but unsure if I was always using properly;</li> <li>3. Always used recommended PPE and paid close attention to donning and doffing</li> </ol>	

NA: not applicable; ICU: intensive care unit; OR: operating room; PPE: personal protective equipment

**eTable 2. Additional descriptive statistics for survey participants (n=9,610).**

<b>Factor</b>	<b>Total sample N. (%)</b>	<b>Seropositive N. (%)</b>
<b>SARS-CoV-2 testing</b>		
Week of serology testing		
4/19/2020	852 (8.9)	40 (4.7)
4/26/2020	1060 (11.0)	40 (3.8)
5/3/2020	874 (9.1)	52 (5.9)
5/10/2020	1954 (20.3)	126 (6.4)
5/17/2020	2270 (23.6)	172 (7.6)
5/24/2020	1721 (17.9)	57 (3.3)
5/31/2020	569 (5.9)	52 (9.1)
6/7/20 - 6/21/20	310 (3.2)	16 (5.2)
<b>Prior illness (fever or respiratory symptoms) since February 1, 2020 &amp; symptoms</b>		
Prior illness, no COVID-19 test		
No	7969 (82.9)	449 (5.6)
Yes	1641 (17.1)	106 (6.5)
Prior illness, negative COVID-19 test		
No	8882 (92.4)	511 (5.8)
Yes	728 (7.6)	44 (6.0)
Previous positive COVID-19 test		
No	9477 (98.6)	431 (4.5)
Yes	133 (1.4)	124 (93.2)
Previous illness (regardless of COVID-19 testing status)		
No	7191 (74.8)	298 (4.1)
Yes	2419 (25.2)	257 (10.6)
Any symptoms		
No	129 (1.3)	12 (9.3)
Yes	2290 (23.8)	245 (10.7)
Not applicable	7191 (74.8)	298 (4.1)
<b>Additional demographics &amp; detailed job location</b>		
Sex		
Female	7456 (77.6)	428 (5.7)
Male	2154 (22.4)	127 (5.9)

**eTable 2. Additional descriptive statistics for survey participants (n=9,610)  
(continued).**

<b>Factor</b>	<b>Total sample N. (%)</b>	<b>Seropositive N. (%)</b>
Job location (dichotomous)		
Medical-surgical- focused on COVID-19 patients	1160 (12.1)	83 (7.2)
Medical-surgical- not focused on COVID-19 patients	2024 (21.1)	120 (5.9)
ICU- focused on COVID-19 patients	1320 (13.7)	87 (6.6)
ICU- not focused on COVID-19 patients	1445 (15.0)	99 (6.9)
OR or peri-operative area	877 (9.1)	51 (5.8)
Other procedure area	609 (6.3)	40 (6.6)
Emergency department	1007 (10.5)	67 (6.7)
Other hospital area	1716 (17.9)	102 (5.9)
Clinic- focused on COVID-19 patients	267 (2.8)	16 (6.0)
Clinic- not focused on COVID-19 patients	2190 (22.8)	115 (5.3)
Non-clinical area of hospital or clinic	1582 (16.5)	84 (5.3)
Not in hospital or clinic	239 (2.5)	12 (5.0)
Work from home	895 (9.3)	42 (4.7)

ICU: intensive care unit; OR: operating room

**eTable 3. STROBE Statement—checklist of items that should be included in reports of observational studies**

	<b>Item No</b>	<b>Recommendation</b>	<b>Page No</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	2-3
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	2-3, eTable 1
Bias	9	Describe any efforts to address potential sources of bias	3
Study size	10	Explain how the study size was arrived at	2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	2-3, eTable 1
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	2-3
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	3
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	2-3



**eTable 3. STROBE Statement—checklist of items that should be included in reports of observational studies (continued)**

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	3
		(b) Give reasons for non-participation at each stage	3
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	3, Table 1, eTable 2
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	3, Table 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	3-4, Table 1
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	3-4
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	4-5
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	5
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	4-5
Generalisability	21	Discuss the generalisability (external validity) of the study results	4-5
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	5

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.